CrushSCI.com
99.0Average days
92.5Median days
30Fastest days
248Longest days
2652025 publications

Paper Review Records

All Paper Review Records

20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

90 days

Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials

Authors
Farida Namozova; Isadora Mamede; Carolina Alves Felippe; Ellen Rodrigues; Carlos SteccaShow moreShow less
Affiliations
1. Tashkent Medical Academy, Tashkent, Uzbekistan; 2. Federal University of São João del-Re, Divinópolis, Brazil; 3. University of Grande Rio “José de Souza Herdy” (UNIGRANRIO), Rio de Janeiro, Brazil; 4. Department of Obstetrics and Gynecology, São Paulo Municipal Health, São Paulo, Brazil; 5. Division of Medical Oncology, BC Cancer, Abbotsford, CanadaShow moreShow less
Source PDF DOI Publisher page
248 days

Current therapeutic interventions to target cancer stem cells for metastasis

Authors
Priyancka Arora; Rakesh Bhatia; Sheetal Sharma; Anupam Sharma; Subhash C. Chauhan; Jagmohan Singh; Anil Kumar SharmaShow moreShow less
Affiliations
1. Department of Biotechnology, Amity School of Biological Sciences, Amity University Punjab, Sahibzada Ajit Singh Nagar, India; 2. Department of Experimental Medicine and Biotechnology, PGIMER Chandigarh, Chandigarh, India; 3. Department of Physics, Guru Kashi University, Talwandi Sabo, Bathinda, India; 4. Department of Microbiology and Immunology, School of Medicine, University of Texas Rio Grande Valley (UTRGV), Edinburg, USAShow moreShow less
Source PDF DOI Publisher page
30 days

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

Authors
Tadayoshi Hashimoto; Taro Shibuki; Takao Fujisawa; Shogen Boku; Mizuho Kikuchi; Atsuko Shimizu; Tomoe Murakami; Yasutoshi Sakamoto; Izumi Miki; Naoko Iida; Haruki Kurano; Riu Yamashita; Jun Masuda; Kensuke Matsuda; Junichiro Yuda; Shugo Yajima; Shin Kobayashi; Zedao Liu; Masataka Amisaki; Mitsuho Imai; Yoshiaki Nakamura; Hideaki Bando; Hyoju Kim; Heon Yung Gee; Hee Seung Lee; Hyun Woo Park; Takayuki YoshinoShow moreShow less
Affiliations
1. Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan; 2. Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 3. Perioperative Treatment Development Promotion Office, National Cancer Center Hospital East, Kashiwa, Japan; 4. Department of Hepato-biliary pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 5. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 6. Department of Clinical Oncology, Kansai Medical University Hospital, Hirakata, Japan; 7. Division of Translational Informatics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan; 8. Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 9. Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan; 10. Department of Urology, National Cancer Center Hospital East, Kashiwa, Japan; 11. Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Japan; 12. Department of Oncology, University of Oxford, Oxford, UK; 13. Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 Four Project, Yonsei University, Seoul, Republic of Korea; 14. Department of Pharmacology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University college of medicine, Seoul, Republic of Korea; 15. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; 16. Global Center of Research Excellence for Advanced Medicine (G-CORE), Keio University School of Medicine, Tokyo, JapanShow moreShow less
Source PDF DOI Publisher page
93 days

Guideline-concordant treatment and clinical outcomes in older patients with endometrial cancer in Japan: a retrospective single-institution study

Authors
Kanako Kasuya; Naoko Komura; Satoshi Nakagawa; Tsuyoshi Takiuchi; Eiji Kobayashi; Kae Hashimoto; Yutaka Ueda; Kenjiro Sawada; Michiko KodamaShow moreShow less
Affiliations
1. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan; 2. Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan; 3. Department of Advanced Prevention and Health Sciences, Wakayama Medical University, Wakayama, Japan; 4. Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Ehime, JapanShow moreShow less
Source PDF DOI Publisher page
156 days

Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches

Authors
Jia Yao; Zhen Liu; Jing Zhang; Xiongzhi Long; Chen Chao; Liqin YuanShow moreShow less
Affiliations
1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2. National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Department of Metabolism and Endocrinology, Ministry of Education, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of ChinaShow moreShow less
Source PDF DOI Publisher page
74 days

Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT 3 receptor antagonists and dexamethasone

Authors
Takeshi Aoyama; Hirotoshi Iihara; Masakazu Abe; Makoto Wada; Keiko Iino; Tatsuo Akechi; Chiyo K. Imamura; Ayako Okuyama; Keiko Ozawa; Yong-Il Kim; Hidenori Sasaki; Eriko Satomi; Masayuki Takeda; Ryuhei Tanaka; Takako Eguchi Nakajima; Naoki Nakamura; Junichi Nishimura; Mayumi Noda; Kazumi Hayashi; Takahiro Higashi; Narikazu Boku; Koji Matsumoto; Yoko Matsumoto; Kenji Okita; Nobuyuki Yamamoto; Kenjiro AogiShow moreShow less
Affiliations
1. Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 2. Department of Pharmacy, Gifu University Hospital, Gifu, Japan; 3. Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan; 4. Department of Psycho-Oncology, Osaka International Cancer Institute, Osaka, Japan; 5. School of Nursing, National College of Nursing, Tokyo, Japan; 6. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 7. Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan; 8. Graduate School of Nursing Science, St. Luke’s International University, Tokyo, Japan; 9. Division of Survivorship, Institute for Cancer Control, National Cancer Center, Tokyo, Japan; 10. Division of Medical Oncology, Yodogawa Christian Hospital, Osaka, Japan; 11. Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, Fukuoka, Japan; 12. Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan; 13. Department of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Japan; 14. Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan; 15. Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan; 16. Department of Radiation Oncology, St. Marianna University, Kawasaki, Japan; 17. Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; 18. Non-profit Organization Sasaeau-kai “Alpha”, Chiba, Japan; 19. Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan; 20. Department of Public Health and Health Policy, The University of Tokyo, Tokyo, Japan; 21. Department of Oncology and General Medicine, Institute of Medical Science, IMSUT Hospital, University of Tokyo, Minato-ku, Tokyo, Japan; 22. Division of Medical Oncology, Hyogo Cancer Center, Akashi, Japan; 23. Non-profit Organization Ehime Cancer Support “Orange-no-kai”, Matsuyama, Japan; 24. Department of Surgery, Otaru Ekisaikai Hospital, Otaru, Japan; 25. Internal Medicine III, Wakayama Medical University, Wakayama, Japan; 26. Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, JapanShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.